
HRMY Earnings
Harmony Biosciences Holdings Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Harmony Biosciences Holdings Inc(HRMY) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Harmony Biosciences Holdings Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-05 | Pre-Market | 0.93 | 0.92 | -1.08 | 204.12M | 200.49M | -1.78 | -1.69 | -3.80 |
FY2025Q1 | 2025-05-06 | Pre-Market | 0.59 | 0.78 | +32.20 | 182.27M | 184.73M | +1.35 | +6.98 | +13.65 |
FY2024Q4 | 2025-02-25 | Pre-Market | 0.74 | 1.08 | +45.95 | 201.25M | 201.27M | +0.01 | +8.16 | -5.85 |
FY2024Q3 | 2024-10-29 | Pre-Market | 0.64 | 0.79 | +23.44 | 184.06M | 186.04M | +1.08 | +16.06 | -7.55 |
FY2024Q2 | 2024-08-06 | - | -0.04 | 0.20 | +600.00 | 172.53M | 172.81M | +0.17 | +6.18 | +8.05 |
FY2024Q1 | 2024-04-30 | - | 0.64 | 0.67 | +4.69 | 154.09M | 154.62M | +0.34 | +5.68 | +5.64 |
FY2023Q4 | 2024-02-22 | - | 0.74 | 0.45 | -39.19 | 168.26M | 168.41M | +0.09 | -4.70 | +0.79 |
FY2023Q3 | 2023-10-31 | - | 0.67 | 0.63 | -5.97 | 148.61M | 160.27M | +7.85 | +19.43 | +26.48 |
FY2023Q2 | 2023-08-01 | - | 0.62 | 0.56 | -9.68 | 142.04M | 134.22M | -5.51 | -3.90 | -5.29 |
- | 2023-05-02 | - | 0.44 | 0.48 | +9.09 | - | - | - | +2.41 | +10.04 |
HRMY Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Harmony Biosciences Holdings Inc reported performance for FY2025Q2, announced on 2025-08-05. The company achieved an EPS of 0.92, compared to analyst estimates of 0.93 by -1.08% . Revenue for the quarter reached 200.49M compared to expectations of 204.12M by -1.78% .
The stock price reacted with a -1.69% one-day change and a -3.80% five-day change following the earnings release. These movements reflect market reaction in Harmony Biosciences Holdings Inc growth trajectory and strategic initiatives.
HRMY Earnings Forecast
Looking ahead, Harmony Biosciences Holdings Inc(HRMY) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 220.52M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.1%, while EPS estimates have been Revise Upward by 1.17%. For the upcoming , revenue estimates have been adjusted Go Up by 5.56% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Harmony Biosciences Holdings Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between HRMY's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+0.1%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Upward

+1.17%
In Past 3 Month
Stock Price
Go Up

+5.56%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:841.46M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price36.28
HRMY Revenue and EPS Performance: A Historical Perspective
Harmony Biosciences Holdings Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-05,Pre-Market):
EPS: 0.92 (Actual) vs.0.93 (Estimate) (-1.08%)
Revenue: 200.49M (Actual) vs. 204.12M (Estimate) (-1.78%)
Price Reaction: -1.69%(1-Day), -3.80%(5-Day)
FY2025Q1 (2025-05-06,Pre-Market):
EPS: 0.78 (Actual) vs.0.59 (Estimate) (32.20%)
Revenue: 184.73M (Actual) vs. 182.27M (Estimate) (1.35%)
Price Reaction: 6.98%(1-Day), 13.65%(5-Day)
FY2024Q4 (2025-02-25,Pre-Market):
EPS: 1.08 (Actual) vs.0.74 (Estimate) (45.95%)
Revenue: 201.27M (Actual) vs. 201.25M (Estimate) (0.01%)
Price Reaction: 8.16%(1-Day), -5.85%(5-Day)
Earnings Reaction
The chart below shows how HRMY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HRMY sees a -1.12% change in stock price 10 days leading up to the earnings, and a +0.52% change 10 days following the report. On the earnings day itself, the stock moves by +5.46%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -0.77% on the day following the earnings release and then changed by 3.84% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Call Summary
Positive
2025-08-05
The earnings call reveals strong financial performance, with a 20% YoY increase in WAKIX revenue and a robust cash position. The pipeline development is promising, with multiple late-stage assets. The reaffirmation of revenue guidance and the expectation for WAKIX to reach a $1 billion opportunity are positive indicators. The Q&A highlights management's confidence in upcoming clinical milestones and strategic collaborations. Despite some uncertainties in the management's responses, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call reveals strong financial performance with a 20% YoY revenue increase and a robust cash position. Despite some concerns about competitive pressures and R&D risks, the company maintains a positive outlook with a catalyst-rich pipeline, promising partnerships, and broad coverage for WAKIX. The Q&A section shows management's confidence in clinical trials and future growth, although some management responses were unclear. Given the market cap, the stock is likely to react positively within the 2% to 8% range due to these strong fundamentals and optimistic guidance.
Harmony Biosciences Holdings Inc (HRMY) Q4 2024 Earnings Call Summary
Neutral
2025-02-25
The earnings call presented mixed signals. Strong financial performance with 23% YoY revenue growth and increased profitability is positive. However, regulatory challenges, particularly with the sNDA for Pitolisant and competition in the narcolepsy market, pose risks. The lack of shareholder return initiatives and unclear management responses in the Q&A further contribute to uncertainty. Given the company's small-cap status, the stock is likely to remain stable, with a potential slight movement within the neutral range (-2% to 2%) over the next two weeks.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Summary
Positive
2024-10-29
The earnings call highlights strong financial performance with a 16% revenue increase and stable net income, despite rising expenses. The FDA approval for pediatric narcolepsy and the $1 billion market potential for WAKIX are promising. The Q&A indicates confidence in product differentiation and market strategy. The company's robust cash position supports pipeline growth, although competitive and regulatory risks exist. The reiterated guidance and potential peak sales for Pitolisant suggest positive sentiment. Given the mid-sized market cap, the stock is likely to experience a positive reaction.
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Summary
Neutral
2024-08-06
The earnings call summary presents a mixed picture. Financial performance is strong with a 29% revenue growth and a solid cash position, but there are concerns about supply chain challenges, economic factors, and intellectual property risks. The Q&A section highlights uncertainties in pediatric market penetration and unclear management responses, which temper overall optimism. The share repurchase program is a positive, but the market's competitive nature and potential challenges could offset gains, leading to a neutral stock price movement prediction.
People Also Watch

NGD
New Gold Inc
5.075
USD
+2.32%

CGON
CG Oncology Inc
24.950
USD
0.00%

SOC
Sable Offshore Corp
28.650
USD
+0.60%

ALG
Alamo Group Inc
228.320
USD
+0.58%

LGIH
LGI Homes Inc
62.405
USD
+1.59%

CXM
Sprinklr Inc
8.015
USD
+0.44%

MGNI
Magnite Inc
22.500
USD
+1.08%

GENI
Genius Sports Ltd
12.470
USD
-2.12%

IBTA
Ibotta Inc
33.660
USD
+2.31%

LU
Lufax Holding Ltd
2.900
USD
+2.84%
FAQ

What were the key highlights of HRMY’s latest earnings report for FY2025Q2?
HRMY reported its FY2025Q2 earnings on 2025-08-05, showcasing a revenue of 200.49M against an estimate of 204.12M, resulting in a -1.78% surprise. The EPS was 0.92, surpassing the expected 0.93 by -1.08% . The stock experienced a -1.69% price change on the earnings day and a -3.8% change over the next five days, reflecting market reactions to the results.

How did HRMY’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for HRMY for 2025/Q3?

How does HRMY’s stock price correlate with earnings forecast revisions?

What should investors expect from HRMY’s next earnings report?
